News & Updates

Show Multimedia Only
Dupilumab trumps MTX, cyclosporine in paediatric AD Dupilumab trumps MTX, cyclosporine in paediatric AD

Dupilumab trumps MTX, cyclosporine in paediatric AD

03 Feb 2025 byStephen Padilla

The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.

03 Feb 2025
COVID-linked MIS-C outcomes reassuring at 6 months

COVID-linked MIS-C outcomes reassuring at 6 months

31 Jan 2025 byElvira Manzano

Children and young adults with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19 infection show good cardiovascular and noncardiovascular outcomes at 6 months, according to data from the long-term MUSIC study.

31 Jan 2025